Side effects of the antipsychotic drug Abilify (generic: aripiprazole) caused a Minnesota woman to rack up a large amount of debt as a result of compulsive gambling, according to a recent lawsuit.
Free Confidential Lawsuit Evaluation: If you or a loved one experienced financial loss, family problems or legal consequences as a result of compulsive gambling while taking Abilify, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.
What’s the Problem?
October 18, 2016 – The lawsuit (PDF) states that Plaintiff Denise Miley took Abilify from September 2014 to February 2015, during which time she accumulated gambling debts in excess of $75,000. When she stopped taking the drug her urge to gamble disappeared; however, by that time the damage had already been done, according to the lawsuit.
Abilify was approved by the U.S. Food & Drug Administration (FDA) in November 2002 as a treatment for schizophrenia, bipolar disorder and major depressive disorder. While schizophrenia is considered to be fairly rare, depression and bipolar disorder are both widespread and growing. In the 14 years since Abilify first hit the U.S. market, at least 24 million prescriptions have been written for the drug.
Miley claims that she had no knowledge about the potential for compulsive gambling with Abilify. However, it appears that defendants Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical Co. did, as Abilify labels in Europe have warned about the risk of such compulsive behaviors for years. No such warning was included on the drug’s labeling in the U.S. until May 2016.
The suit further alleges that the absence of a gambling warning in the U.S. translated into massive profits for the manufacturers. U.S. Revenues from Abilify amounted to $417 million over the first 3 months of 2014, compared to $555 million worldwide during the same period, according to the lawsuit. Miley alleges that revenues would have been significant lower had the gambling warning been included on Abilify labels in the U.S.
The lawsuit (case number 0:16-cv-00067) was filed on January 12, 2016, in the U.S. District Court for the District of Minnesota, and was transferred to the Abilify multidistrict litigation (MDL No. 2734) in the Northern District of Florida on October 3, 2016.
Do I Have an Abilify Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Case Evaluation: Again, if you experienced compulsive behaviors after taking Abilify, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.